| 1. |
|
|
| 2. |
- Bölükbas, D. A., et al.
(författare)
-
Fine-tuning lung cancer nanotherapy using closed cardiopulmonary circulation
- 2019
-
Ingår i: Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium : 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence. - 9781510883901 ; 40
-
Konferensbidrag (refereegranskat)abstract
- Statement of Purpose: Lung cancer is the leading cause of cancer-related deaths and efficient therapies remain elusive. One emerging approach is to use nanoparticles (NPs) that are designed to specifically target malignant cells (1). Such targeting increases on-site drug doses and reduces systemic side effects. A common target in lung tumors is epidermal growth factor receptor (EGFR). Here, we explored the targeting efficacy of EGFR-targeted mesoporous silica nanoparticles (MSN GE11 ) for lung cancer treatment. Though specifically taken up by cancer cells in vitro, when administered intravenously or intratracheally in lung cancer mouse models, the NPs could not reach the depths of solid tumors and often strayed away from their target. This raises concerns whether NPs are suitable for therapeutically targeting lung tumors and challenges translational value of current approaches. To circumvent physiological barriers of solid lung tumors and consequent systemic clearance of NPs, we extended our analysis to a treatment strategy where the NPs are administered intravenously in a closed cardiopulmonary (CP) circulation loop. This approach not only makes the therapy more local, but also eliminates confounding factors for NP delivery such as liver/spleen deposition of NPs in vivo.
|
|
| 3. |
- Bein, D., et al.
(författare)
-
Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI
- 2011
-
Ingår i: Journal of the European Academy of Dermatology and Venereology. - : Wiley. - 0926-9959 .- 1468-3083. ; 25:6, s. 652-659
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a scoring system for patients with cutaneous lupus erythematosus (CLE) to assess disease activity and damage. Objective: The aim of this study was to evaluate whether the CLASI is a useful instrument which reflects the different subtypes of CLE comparably well in each parameter. Methods: A total of 50 patients (42 female, 8 male) with different subtypes of CLE, including acute CLE (ACLE), subacute CLE (SCLE), chronic CLE (CCLE) and LE tumidus (LET), from the Departments of Dermatology, University of Dusseldorf, Germany, and Danderyd Hospital, Stockholm, Sweden, were evaluated using the CLASI at one time point. Results: The total CLASI activity score was significantly lower in patients with LET compared with ACLE (P < 0.05) and CCLE (P < 0.001), and the total CLASI damage score was significantly lower in patients with LET than with ACLE (P < 0.05), SCLE (P < 0.001) and CCLE (P < 0.001). The erythema score and the scale/hypertrophy score were significantly lower in LET than in ACLE (P < 0.05, both) and CCLE (P < 0.05 and P < 0.001, respectively). The dyspigmentation score was lowest in patients with LET, differing significantly from ACLE (P < 0.05), SCLE (P < 0.05) and CCLE (P < 0.001). The scarring/atrophy/panniculitis score was significantly higher in patients with CCLE in contrast to SCLE and LET (P < 0.05 and P < 0.001, respectively). Conclusion: These data characterize the CLASI as an overall useful instrument to analyse disease activity and damage in CLE. However, the CLASI does not give an accurate assessment of all disease subtypes; therefore, a revision of the CLASI with critical analysis of all parameters is recommended.
|
|
| 4. |
|
|
| 5. |
- Bein, T., et al.
(författare)
-
Enhanced Lightweight Design - First Results of the FP7 Project ENLIGHT
- 2016
-
Ingår i: Transportation Research Procedia. - : Elsevier B.V.. - 2352-1465. ; , s. 1031-1040
-
Tidskriftsartikel (refereegranskat)abstract
- The European Green Vehicle project ENLIGHT aims to advance highly innovative lightweight material technologies for application in structural vehicle parts of future volume produced Electric Vehicles (EVs) along four axes: performance, manufacturability, cost effectiveness and lifecycle footprint. The main target is to develop viable and sustainable solutions for medium production volume up to 50.000 EVs destined to reach the market in the next 8-12 years. The specific objectives of the ENLIGHT project are on holistic and integrated conceptual design and manufacturing concerning how the technologies and materials addressed can be combined into a representative medium-volume EV. The solutions will be demonstrated in five modules: a front module and central floor module, a front door, a sub-frame and suspension system as well as a cross-car beam. In this paper, a summary of the major results obtained up to the 3rd project year will be presented. © 2016 The Authors.
|
|
| 6. |
|
|
| 7. |
- Bein, T, et al.
(författare)
-
Ventilation-perfusion relationships in acute respiratory failure
- 1996
-
Ingår i: ANAESTHESIST. - : SPRINGER VERLAG. ; 45:4
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Acute respiratory failure is characterised by mismatch of ventilation with perfusion (V-A/Q). The multiple inert gas elimination technique (MIGET) is a complex method which allows the description of a virtually continuous distribution of V-A/Q ratios. We
|
|
| 8. |
- Bölükbas, Deniz, et al.
(författare)
-
Organ-Restricted Vascular Delivery of Nanoparticles for Lung Cancer Therapy
- 2020
-
Ingår i: Advanced Therapeutics. - : Wiley. - 2366-3987. ; 3:7
-
Tidskriftsartikel (refereegranskat)abstract
- Nanoparticle-based targeted drug delivery holds promise for treatment of cancers. However, most approaches fail to be translated into clinical success due to ineffective tumor targeting in vivo. Here, the delivery potential of mesoporous silica nanoparticles (MSN) functionalized with targeting ligands for epidermal growth factor receptor and C─C chemokine receptor type 2 is explored in lung tumors. The addition of active targeting ligands on MSNs enhances their uptake in vitro but fails to promote specific delivery to tumors in vivo, when administered systemically via the blood or locally to the lung into immunocompetent murine lung cancer models. Ineffective tumor targeting is due to efficient clearance of the MSNs by the phagocytic cells of the liver, spleen, and lung. These limitations, however, are successfully overcome using a novel organ-restricted vascular delivery (ORVD) approach. ORVD in isolated and perfused mouse lungs of Kras-mutant mice enables effective nanoparticle extravasation from the tumor vasculature into the core of solid lung tumors. In this study, ORVD promotes tumor cell-specific uptake of nanoparticles at cellular resolution independent of their functionalization with targeting ligands. Organ-restricted vascular delivery thus opens new avenues for optimized nanoparticles for lung cancer therapy and may have broad applications for other vascularized tumor types.
|
|
| 9. |
- Gräsner, J. -T, et al.
(författare)
-
Epidemiology of cardiac arrest in Europe : European Resuscitation Council Guidelines 2021
- 2021
-
Ingår i: Notfall & Rettungsmedizin. - : Springer Medizin. - 1434-6222 .- 1436-0578. ; 24:4, s. 346-366
-
Tidskriftsartikel (refereegranskat)abstract
- In this section of the European Resuscitation Council Guidelines 2021, key information on the epidemiology and outcome of in- and out-of-hospital cardiac arrest are presented. Key contributions from the European Registry of Cardiac Arrest (EuReCa) collaboration are highlighted. Recommendations are presented to enable health systems to develop registries as a platform for quality improvement and to provide support for health system planning and responses to cardiac arrest.
|
|
| 10. |
- Gräsner, J. -T, et al.
(författare)
-
European Resuscitation Council Guidelines 2021 : Epidemiology of cardiac arrest in Europe
- 2021
-
Ingår i: Resuscitation. - : Elsevier. - 0300-9572 .- 1873-1570. ; 161, s. 61-79
-
Tidskriftsartikel (refereegranskat)abstract
- In this section of the European Resuscitation Council Guidelines 2021, key information on the epidemiology and outcome of in and out of hospital cardiac arrest are presented. Key contributions from the European Registry of Cardiac Arrest (EuReCa) collaboration are highlighted. Recommendations are presented to enable health systems to develop registries as a platform for quality improvement and to inform health system planning and responses to cardiac arrest.
|
|
